{
  "meta": {
    "title": "Breast_Disorders",
    "url": "https://brainandscalpel.vercel.app/breast-disorders-ebe867ef.html",
    "scrapedAt": "2025-11-29T18:32:19.326Z"
  },
  "questions": [
    {
      "id": 41591,
      "choices": [
        {
          "id": 166052,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Invasive ductal carcinoma</span></span></span></p>"
        },
        {
          "id": 166053,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Invasive lobular carcinoma</span></span></span></p>"
        },
        {
          "id": 166054,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medullary carcinoma</span></span></span></p>"
        },
        {
          "id": 166055,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ductal carcinoma in situ (DCIS)</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old woman undergoes a breast biopsy after a suspicious mammogram. Histological examination reveals a tumor with lack of tubule formation, discohesive cells and a low mitotic rate. Immunohistochemistry shows positive estrogen receptor (ER) and progesterone receptor (PR) staining. What is the most likely histological type of breast cancer?</span></span></span></p>",
      "unique_key": "Q6982660",
      "question_audio": null,
      "question_video": null,
      "map_id": 32514,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Invasive lobular carcinoma</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Invasive lobular carcinoma&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(ILC) is characterized by a <strong>lack of tubule formation</strong>, <strong>discohesive cells </strong>that <strong>infiltrate the stroma in a single-file pattern</strong>, and a <strong>low mitotic rate</strong>. <strong>ILC </strong>is often <strong>ER and PR positive</strong>. The classic <strong>histological features </strong>include a <strong>targetoid appearance</strong>, known as <strong>&quot;Indian file&quot; pattern</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Invasive ductal carcinoma</strong> tends to form <strong>glandular structures </strong>and does not usually present with the &quot;Indian file&quot; pattern of cell arrangement seen in invasive lobular carcinoma.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Medullary carcinoma</strong> has a <strong>higher mitotic rate </strong>and a <strong>lymphocytic infiltrate</strong>, which differs from the low mitotic rate and discohesive cells described in the biopsy report.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>Ductal carcinoma</strong> <strong>in situ</strong> represents an <strong>early form of breast cancer </strong>that is <strong>confined to the ducts </strong>and usually forms duct-like structures, unlike the pattern described.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Invasive lobular carcinoma </strong>is characterized by the <strong>absence of tubule formation</strong>, <strong>discohesive cells</strong>, a <strong>low mitotic rate</strong>, and <strong>positive hormone receptor status</strong>.</span></span></span></p>",
      "correct_choice_id": 166053,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16877,
      "choices": [
        {
          "id": 67468,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Apocrine DCIS</span></span></span></p>"
        },
        {
          "id": 67469,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Neuroendocrine DCIS </span></span></span></p>"
        },
        {
          "id": 67470,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Will-differentiated DCIS </span></span></span></p>"
        },
        {
          "id": 67471,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Comedo DCIS</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 47-year-old woman presents for evaluation of a hard, poorly defined mass in her left breast. She reports no pain or discharge, but she has noted a recent change in the shape of the breast. There is no family history of breast cancer. A mammogram reveals microcalcifications in the upper outer quadrant of the left breast. A biopsy of the lesion is performed. </span></span><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The type of mammary ductal carcinoma in situ (DCIS) most likely to result in a palpable abnormality in the breast is:</span></span></p>",
      "unique_key": "Q9019592",
      "question_audio": null,
      "question_video": null,
      "map_id": 32509,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Comedo DCIS </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">DCIS&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">most frequently presents as <strong>mammographic calcifications</strong>. Less typically DCIS may present as a <strong><em>vaguely palpable mass</em></strong>. This is most likely with <strong><em>Comedocarcinomas</em></strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Comedo DCIS </strong>often <strong>presents with high-grade necrotic cells </strong>and <strong>dystrophic calcifications</strong>, which can be <strong>detected on mammography </strong>and may also <strong>form a palpable mass</strong>, consistent with the patient&rsquo;s presentation.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Apocrine DCIS</strong> presents with <strong>characteristic apocrine cytologic features under microscopy </strong>but is not the most likely to form a palpable mass.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Neuroendocrine DCIS</strong> is a <strong>rare form </strong>and typically does not present as a palpable lesion in the breast.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Well-differentiated DCIS</strong> may <strong>show microcalcifications </strong>on <strong>mammography</strong>, but palpable masses are less common than in the comedo subtype.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Comedo DCIS </strong>is most likely to <strong>present as a palpable mass </strong>due to the <strong>associated necrosis </strong>and <strong>calcifications</strong>. It is often <strong>found on mammography </strong>and can <strong>form a more solid</strong>, <strong>palpable lesion </strong>compared to other subtypes of DCIS.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 1060</span></strong></span></span></p>",
      "correct_choice_id": 67471,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16881,
      "choices": [
        {
          "id": 67484,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nottingham</span></span></span></p>"
        },
        {
          "id": 67485,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Birmingham</span></span></span></p>"
        },
        {
          "id": 67486,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cunningham</span></span></span><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;</span></span></span></p>"
        },
        {
          "id": 67487,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Welham</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All invasive breast carcinomas are graded histologically with the following scoring system:</span></span></p>",
      "unique_key": "Q4197855",
      "question_audio": null,
      "question_video": null,
      "map_id": 32510,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Nottingham</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Breast carcinomas </strong>are histologically graded using the <strong>Nottingham Histologic Score</strong>, also known as the <strong>Nottingham Combined Histologic Grade </strong>or <strong>Nottingham Grading System</strong>. This system evaluates <strong>three histologic features</strong>: <strong>tubule formation</strong>, <strong>nuclear pleomorphism</strong>, and <strong>mitotic count</strong>. Each component is assigned a score, and the scores are combined to determine the overall grade. This grading system helps in predicting the behavior and prognosis of breast cancer.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>Nottingham Histologic Score </strong>is used for <strong>grading breast carcinomas</strong>. It <strong>assesses tubule formation</strong>, <strong>nuclear pleomorphism</strong>, and <strong>mitotic count</strong>, each of which is given a score.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 1064</span></strong></span></span></p>",
      "correct_choice_id": 67484,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41588,
      "choices": [
        {
          "id": 166040,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Polymerase Chain Reaction (PCR)</span></span></span></p>"
        },
        {
          "id": 166041,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fluorescence In Situ Hybridization (FISH)</span></span></span></p>"
        },
        {
          "id": 166042,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Southern Blotting</span></span></span></p>"
        },
        {
          "id": 166043,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Western Blotting</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old woman presents with a suspicious breast mass. A core biopsy is performed, and immunohistochemistry (IHC) reveals a HER2/neu score of 2. Given the equivocal HER2 status, which technique is most appropriate for further evaluation to determine the HER2/neu gene amplification status?</span></span></p>",
      "unique_key": "Q9082804",
      "question_audio": null,
      "question_video": null,
      "map_id": 32511,
      "difficulty_level": "beginner",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>B)</strong> <strong>Fluorescence In Situ Hybridization (FISH)</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fluorescence In Situ Hybridization (FISH)&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is a <strong>molecular cytogenetic technique </strong>that can be used to <strong>detect and quantify the presence of specific DNA sequences</strong>. In the context of breast cancer, FISH is commonly used to assess the amplification of the HER2/neu gene. <strong><em>A HER2/neu score of 2 by IHC is considered equivocal, and FISH is recommended to further evaluate the gene amplification status</em></strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Polymerase Chain Reaction (PCR</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">) is a <strong>technique </strong>used to <strong>amplify DNA </strong>but is not typically employed to assess gene amplification status. It is more suitable for studying the presence or absence of specific DNA sequences.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Southern blotting</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a technique used to <strong>detect specific DNA sequences </strong>in a <strong>DNA sample</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Western blotting</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a technique used to <strong>detect specific proteins in a sample</strong>. It is not applicable to assess gene amplification and is more suited for protein analysis.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In cases of <strong>equivocal HER2/neu IHC </strong>results which is <strong>IHC score of 2</strong>, further recommended technique is <strong>Fluorescence In Situ Hybridization </strong>(FISH) for evaluation of <strong>HER2/neu gene amplification status </strong>in <strong>breast cancer</strong>.</span></span></span></p>",
      "correct_choice_id": 166041,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41589,
      "choices": [
        {
          "id": 166044,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Initiate hormonal therapy with tamoxifen</span></span></span></p>"
        },
        {
          "id": 166045,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Administer chemotherapy with doxorubicin and cyclophosphamide</span></span></span></p>"
        },
        {
          "id": 166046,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prescribe trastuzumab </span></span></span></p>"
        },
        {
          "id": 166047,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recommend radiotherapy for local control</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman presents with a palpable lump in her left breast. A biopsy is performed, and the histopathological examination reveals invasive ductal carcinoma. Immunohistochemistry (IHC) shows a HER2/neu score of 3+. What is the most appropriate next step in managing this patient&#39;s breast cancer?</span></span></p>",
      "unique_key": "Q6733957",
      "question_audio": null,
      "question_video": null,
      "map_id": 32512,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Prescribe trastuzumab</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trastuzumab</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, given its <strong>ability to target HER2/neu-positive tumors</strong>, would be the most appropriate <strong>next step in management </strong>for a patient with a HER2/neu score of 3+ on IHC.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While <strong>hormonal therapy </strong>is an essential part of the <strong>treatment for hormone receptor-positive breast cancer</strong>, the HER2/neu status of the tumor guides the use of targeted therapies such as trastuzumab.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Chemotherapy </strong>may be a <strong>component of treatment for breast cancer, </strong>but for HER2/neu-positive tumors, trastuzumab is a key targeted therapy that has been shown to significantly improve outcomes.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Radiotherapy </strong>could be part of the <strong>comprehensive treatment for breast cancer</strong>, particularly for local control, but is not directly related to the HER2/neu overexpression finding.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For a patient with a <strong>HER2/neu score of 3+ indicating HER2 protein overexpression</strong>, <strong>trastuzumab </strong>is the most appropriate next step for targeted therapy in the management of HER2-positive breast cancer.</span></span></span></p>",
      "correct_choice_id": 166046,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41590,
      "choices": [
        {
          "id": 166048,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An aromatase inhibitor </span></span></span></p>"
        },
        {
          "id": 166049,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Selective estrogen receptor modulator (SERM) like tamoxifen</span></span></span></p>"
        },
        {
          "id": 166050,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gonadotropin-releasing hormone agonist</span></span></span></p>"
        },
        {
          "id": 166051,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Progestin therapy</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old postmenopausal woman is diagnosed with estrogen receptor-positive (ER+) and progesterone receptor-positive (PR+) invasive lobular carcinoma of the breast. What is the most appropriate adjuvant endocrine therapy for this patient?</span></span></p>",
      "unique_key": "Q4657524",
      "question_audio": null,
      "question_video": null,
      "map_id": 32513,
      "difficulty_level": "difficult",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) An aromatase inhibitor</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For <strong>postmenopausal women </strong>with <strong>hormone receptor-positive breast cancer</strong>, <strong>aromatase inhibitors </strong>(e.g., letrozole, anastrozole, exemestane) are often preferred <strong>over tamoxifen</strong>. <strong>Aromatase inhibitors reduce </strong>the <strong>production of estrogen </strong>and are associated with <strong>improved disease-free survival </strong>in this <strong>population</strong>. <strong>Tamoxifen </strong>is more commonly used in <strong>premenopausal women</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aromatase inhibitors</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> are typically the <strong>first choice for ER+ breast cancer </strong>in <strong>postmenopausal women </strong>because they are <strong>effective at reducing the amount of estrogen </strong>produced by <strong>adipose </strong>and <strong>other tissues</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Tamoxifen, a SERM</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, can be <strong>used in postmenopausal women </strong>but is often reserved for those who <strong>cannot tolerate aromatase inhibitors </strong>or for premenopausal women.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Gonadotropin-releasing</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>hormone agonists</strong> are used in <strong>premenopausal women </strong>to <strong>suppress ovarian estrogen production</strong>, which is not applicable in postmenopausal women.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Progestin therapy</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is not typically used in the treatment of <strong>hormone receptor-positive breast cancer</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a <strong>postmenopausal woman </strong>with <strong>ER+ and PR+ breast cancer</strong>, the most appropriate adjuvant <strong>endocrine therapy </strong>is an <strong>aromatase inhibitor</strong>, which has been shown to be more <strong>effective than tamoxifen </strong>in this patient population.</span></span></span></p>",
      "correct_choice_id": 166048,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 41592,
      "choices": [
        {
          "id": 166056,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Invasive ductal carcinoma</span></span></span></p>"
        },
        {
          "id": 166057,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fibroadenoma</span></span></span></p>"
        },
        {
          "id": 166058,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ductal carcinoma in situ (DCIS)</span></span></span></p>"
        },
        {
          "id": 166059,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phylloides tumor</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old woman presents with a painless breast lump that has been gradually increasing in size over the past few months. On examination, a well-defined, mobile, rubbery mass is palpable in the upper outer quadrant of her left breast. Mammography reveals a well-circumscribed, round mass without microcalcifications. What is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q7688906",
      "question_audio": null,
      "question_video": null,
      "map_id": 32515,
      "difficulty_level": "beginner",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Fibroadenoma</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fibroadenomas&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">are common <strong>benign breast tumors </strong>in <strong>young women</strong>. They are typically <strong>well-circumscribed</strong>, <strong>mobile</strong>, and <strong>rubbery </strong>on <strong>palpation</strong>. <strong>Mammography </strong>shows a <strong>round mass without microcalcifications</strong>. They are hormonally responsive and may fluctuate in size during the menstrual cycle. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Invasive Ductal Carcinoma (IDC):&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">it is the </span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">most common type of breast cancer. It often presents as an irregularly shaped mass with spiculated margins on imaging. Microcalcifications are a common finding in IDC. Unlike fibroadenomas, IDC tends to infiltrate surrounding tissues invasively.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Ductal Carcinoma in Situ (DCIS):&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">it is a </span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>non-invasive condition </strong>where <strong>abnormal cells are found in the lining </strong>of a <strong>breast duct </strong>but have not invaded surrounding tissues. It is usually detected through mammography and does not typically present as a palpable mass. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Phylloides Tumor&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">are <strong>rare fibroepithelial tumors </strong>that may <strong>mimic fibroadenomas clinically</strong>. They are typically <strong>larger </strong>than <strong>fibroadenomas </strong>and may have a <strong>leaf-like appearance on imaging</strong>. Phylloides tumors have a potential for rapid growth and a higher risk of recurrence compared to fibroadenomas.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Fibroadenoma </strong>is the most likely diagnosis for a <strong>young woman </strong>presenting with a <strong>well-defined, mobile, rubbery breast mass </strong>and a <strong>mammogram </strong>showing a <strong>well-circumscribed, non-calcified round lesion.</strong></span></span></span></p>",
      "correct_choice_id": 166057,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16860,
      "choices": [
        {
          "id": 67400,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">6 </span></span></span></p>"
        },
        {
          "id": 67401,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">11</span></span></span></p>"
        },
        {
          "id": 67402,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">18 </span></span></span></p>"
        },
        {
          "id": 67403,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">32</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A female presented in the gynecology OPD with the presentation as given in the image. The examination revealed presence of high-risk HPV. Which of the following is the causative agent?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/05/28/untitled-547.jpg\" style=\"height:253px; width:300px\" /></span></span></p>",
      "unique_key": "Q4169318",
      "question_audio": null,
      "question_video": null,
      "map_id": 32516,
      "difficulty_level": "beginner",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) 18 </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The question has an image showing <strong>multiple vagino-cervical warts</strong>. If we read the stem of the question, it makes a mention of <strong>high-risk HPV subtype</strong> and so, the answer is <strong>HPV 16</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HPV 18</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is the <strong>correct answer</strong>. It is one of the <strong>high-risk HPV types </strong>known to be associated with <strong>cervical cancer </strong>and <strong>high-grade dysplasia</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. HPV 6</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is incorrect because it is <strong>associated with low-risk lesions </strong>such as <strong>genital warts </strong>rather than high-risk cervical pathologies.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. HPV 11</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is also incorrect for the <strong>same reason as HPV 6</strong>; it is linked to benign lesions and not high-risk cervical dysplasias or cancers.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. HPV 32</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is not typically <strong>implicated in high-risk cervical disease</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>HPV 16 </strong>and <strong>18 are involved in the pathogenesis </strong>of <strong>high-grade cervical dysplasias </strong>and <strong>cervical cancer</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 1001</span></strong></span></span></p>",
      "correct_choice_id": 67402,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16867,
      "choices": [
        {
          "id": 67428,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Blood vessel penetration by tumor cells</span></span></span></p>"
        },
        {
          "id": 67429,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tumor cells in lymphatic channels</span></span></span></p>"
        },
        {
          "id": 67430,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lymphocyte infiltration </span></span></span></p>"
        },
        {
          "id": 67431,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The number of mitoses per high power field</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">With regard to the malignant behavior of leiomyosarcoma, the most important criterion is:</span></span></p>",
      "unique_key": "Q8762571",
      "question_audio": null,
      "question_video": null,
      "map_id": 32508,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) The number of mitoses per high power field </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>most important criterion</strong> for <strong>distinction of leiomyosarcoma </strong>from <strong>leiomyoma </strong>(malignant transformation) is the <strong>number of mitoses present</strong>. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ten high power fields </strong>(hpf) are <strong>examined</strong>. If<strong> &gt; 10 mitoses</strong> are seen, it <strong>signifies malignancy</strong>. If <strong>cellular atypia </strong>is also <strong>present</strong>, <strong>&gt; 5 mitoses </strong>are enough to make a <strong>diagnosis of leiomyosarcoma.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When <strong>distinguishing leiomyosarcoma from leiomyoma</strong>, the <strong>assessment of malignancy </strong>heavily <strong>relies on histological examination</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The number of mitoses per high power field</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a key <strong>histological criterion </strong>to determine the <strong>malignant behavior of leiomyosarcoma</strong>. A higher number of mitotic figures usually indicates a more aggressive tumor.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Blood vessel penetration by tumor cells</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a <strong>feature observed in malignant tumors</strong>. However, while significant, it is not the most critical factor in diagnosing leiomyosarcoma.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. The presence of tumor cells in lymphatic channels</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is another <strong>indication of potential malignancy </strong>and can signify the spread of cancer, but it&#39;s not the primary criterion for diagnosis.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Lymphocyte infiltration</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is often a <strong>sign of an immune response to the tumor </strong>rather than a direct indication of malignancy.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A <strong>high mitotic index </strong>is indicative of <strong>aggressive tumor behavior </strong>and <strong>malignancy</strong>, aiding in the <strong>differentiation between benign </strong>and <strong>malignant smooth muscle tumors </strong>such as <strong>leiomyomas </strong>and <strong>leiomyosarcomas</strong>, respectively. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 1021</span></strong></span></span></p>",
      "correct_choice_id": 67431,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}